文献速递生殖医学妇科

卡铂与紫杉醇对BRCA1突变年轻乳腺癌患者卵巢储备的性腺毒性

Carboplatin and paclitaxel induced-gonadotoxicity on the ovarian reserve of young breast cancer patients with BRCA1 mutation.
PubMed 文献 · Hum Reprod · 2025-01-01

研究将BRCA1突变型(n=4)与非突变型(n=4)乳腺癌患者的冻存卵巢组织片段,经体外培养或小鼠异种移植后暴露于卡铂和/或紫杉醇。结果显示两种基因背景的性腺毒性相似,BRCA1突变患者低于35岁的卵泡并未对化疗更敏感,但DNA修复机制似乎受到差异性影响。

要点

  • 异种移植后化疗组静息卵泡比例较对照升高,无论BRCA状态(BRCA+:79.6±5.07% vs 35.4±8.26%,P=0.0003;BRCA-:81.8±10.50% vs 17.9±21.93%,P=0.0014)。
  • 化疗使DNA断裂率升高(BRCA+:37-49%,BRCA-:43-55%),高于对照(BRCA+:13-19%,BRCA-:17-23%)。
  • 体外单用卡铂时,BRCA突变组织凋亡卵泡率低于非突变组织(41% vs 56%,P=0.0184),γH2AX阳性卵泡率亦较低(20% vs 42%,P=0.0142)。

核心结论

  • 卡铂和紫杉醇对BRCA1突变与非突变乳腺癌患者卵巢组织的性腺毒性相似,BRCA1突变患者低于35岁的卵泡并未对化疗更敏感,但DNA修复机制似乎受到差异性影响。

研究设计与样本

  • 研究采用冻存卵巢组织片段,来自携带BRCA1胚系突变(n=4)或不携带(n=4)的乳腺癌患者。
  • 暴露模型包括体外培养3天(卡铂10 µg/ml、紫杉醇1 µM、两药联合或溶剂对照)和异种移植至免疫缺陷小鼠腹腔后3周注射(卡铂50 mg/kg/周、紫杉醇10 mg/kg/每3天或生理盐水对照)。

主要发现

  • 体外化疗未显著影响原始卵泡比例;异种移植后化疗组静息卵泡比例较各自对照升高(BRCA+:79.6±5.07% vs 35.4±8.26%,P=0.0003;BRCA-:81.8±10.50% vs 17.9±21.93%,P=0.0014)。
  • 卵泡闭锁率无差异,但TUNEL检测显示化疗单用或联合均使DNA断裂率升高(BRCA+:37-49%,BRCA-:43-55%),高于对照(BRCA+:13-19%,BRCA-:17-23%),体外和体内均如此。
  • 体外(两组)和体内(BRCA突变组织)γH2AX染色卵泡较各自对照显著增加。
  • 体外单用卡铂时,BRCA突变组织凋亡卵泡率低于非突变组织(41% vs 56%,P=0.0184),γH2AX阳性卵泡率亦较低(20% vs 42%,P=0.0142)。

临床怎么用

  • 作者认为,这些结果有助于为BRCA1突变患者提供合适的生育力保存咨询。

局限性

  • 对人体组织尤其是年轻BRCA突变患者捐赠的稀有卵巢组织进行实验存在局限性。
  • 研究受样本量小和患者内及患者间高变异性限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are ovarian tissue fragments from patients with BReast CAncer gene 1 (BRCA1)-mutated breast cancer (BC) more sensitive to carboplatin and/or paclitaxel exposure compared to those from non-mutated patients with BC? SUMMARY ANSWER: Carboplatin and paclitaxel treatment showed similar gonadotoxicity, irrespective of the genetic background. WHAT IS KNOWN ALREADY: Studies have shown that mutations of BRCA1 gene negatively impact the ovarian reserve due to defects in DNA repair mechanisms. As a result, patients with BRCA germline mutations might be more vulnerable to chemotherapy-induced gonadotoxicity. Carboplatin and paclitaxel are known moderately gonadotoxic drugs, but the impact of their combination on fertility remains unclear, particularly in BRCA-mutated patients. STUDY DESIGN, SIZE, DURATION: Cryopreserved ovarian tissue fragments from patients with BC, either carrying a BRCA1 germline mutation (n = 4) or not (n = 4), were exposed to chemotherapy using two models: (i) in vitro culture or (ii) in vivo xenotransplantation model. First, thawed ovarian tissue fragments were cultured for 3 days with carboplatin (10 µg/ml), paclitaxel (1 µM), carboplatin, and paclitaxel or vehicle (dimethyl sulfoxide). Next, ovarian tissue fragments from the same patients were xenografted into the peritoneum of immunodeficient mice, followed by 3-week injections with either carboplatin (50 mg/kg/week) and paclitaxel (10 mg/kg/every 3 days) or saline solution as a control. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ovarian cortex was processed for histological analyses to assess follicle activation and survival in both experimental models. Follicle counting and morphological assessment were performed to evaluate the rates of follicles at different developmental stages, as well as the rate of atretic follicles. Immunostainings were performed for follicle activation (KL and p-RPS6), apoptosis (Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) assay), and DNA repair mechanisms (γH2AX, RAD51, and DNA PKcs). MAIN RESULTS AND THE ROLE OF CHANCE: While chemotherapy exposure did not significantly affect the proportion of primordial follicles in vitro, an increase in the proportion of quiescent follicles was observed after xenografting in the treated conditions compared to their respective controls, regardless of the presence of a BRCA mutation (BRCA+: 79.6 ± 5.07% versus 35.4 ± 8.26%, P = 0.0003; BRCA-: 81.8 ± 10.50% versus 17.9 ± 21.93%, P = 0.0014), reflecting the massive destruction of the pool of growing follicles. No difference was observed in the rate of atretic follicles, but the TUNEL assay revealed that chemotherapy, alone or in combination, increased DNA fragmentation rates (BRCA+: 37-49%; BRCA-: 43-55%) compared to the control conditions (BRCA+: 13-19%; BRCA-: 17-23%) both in vitro and in vivo. DNA repair mechanisms were affected following chemotherapy exposure, as evidenced by a significant increase in γH2AX-stained follicles in vitro (both populations) and in vivo (BRCA-mutated tissue) compared to the respective controls. Finally, chemotherapy had a similar impact on follicular atresia and apoptosis in both populations. However, BRCA-mutated tissue had lower rates of apoptotic (41% in BRCA+ versus 56% in BRCA-; P = 0.0184) and γH2AX-positive follicles (20% in BRCA+ versus 42% in BRCA-; P = 0.0142) than non-mutated fragments when exposed to carboplatin alone in vitro. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Experiments on human tissue have limitations, particularly with rare material such as ovarian tissue from young BRCA-mutated patients donated for research. The study is limited by the small sample size and high intra- and inter-patient variability. WIDER IMPLICATIONS OF THE FINDINGS: Studies on BRCA-mutated ovarian tissue are essential to better understand how BRCA mutations impact the ovarian reserve and respond to gonadotoxic treatments. Unexpectedly, this study suggested that follicles from young BRCA-mutated patients below 35 are not more sensitive to chemotherapy than the one from non-mutated patients, although DNA repair mechanisms seems to be differentially affected. Altogether, the results can help to provide appropriate fertility preservation counseling in BRCA1-mutated patients. STUDY FUNDING/COMPETING INTEREST(S): This study is funded by Télévie, a grant of the Fonds National de la Recherche Scientifique-FNRS (Grant Nos 7.4531.22 and 7.6509.24), the Fondation contre le Cancer (Grant No. FAF-C/2018/1274), and supported by Fonds Erasme. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Dias Nunes J, Ntemou E, Van den Steen G, et al. Carboplatin and paclitaxel induced-gonadotoxicity on the ovarian reserve of young breast cancer patients with BRCA1 mutation. Hum Reprod. 2025. PMID: 40646715. doi:10.1093/humrep/deaf133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。